E. Tabolacci and P. Chiurazzi, Epigenetics, fragile X syndrome and transcriptional therapy, Am. J. Med. Genet. A, vol.161, issue.11, pp.2797-2808, 2013.

W. S. Post, P. J. Goldschmidt-clermont, and C. C. Wilhide, Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system, Cardiovasc. Res, vol.43, issue.4, pp.985-991, 1999.

A. O. Arguelles, S. Meruvu, J. D. Bowman, and M. Choudhury, Are epigenetic drugs for diabetes and obesity at our door step?, Drug Discov. Today, vol.21, issue.3, pp.499-509, 2016.

J. Li, D. Hao, and L. Wang, Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy, Sci. Rep, vol.7, issue.1, p.4035, 2017.

E. Kaminskas, A. T. Farrell, Y. C. Wang, R. Sridhara, and R. Pazdur, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension, Oncologist, vol.10, issue.3, pp.176-182, 2005.

, ? Reports the interest to use DNA methyltransferase inhibitors in anticancer therapy

H. Kantarjian, J. P. Issa, and C. S. Rosenfeld, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study, Cancer, vol.106, issue.8, pp.1794-1803, 2006.

L. Schermelleh, A. Haemmer, and F. Spada, Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation, Nucleic Acids Res, vol.35, issue.13, pp.4301-4312, 2007.

K. Schneider, C. Fuchs, and A. Dobay, Dissection of cell cycle-dependent dynamics of Dnmt1 by FRAP and diffusion-coupled modeling, Nucleic Acids Res, vol.41, issue.9, pp.4860-4876, 2013.

E. Hervouet, A. Nadaradjane, M. Gueguen, F. M. Vallette, and P. F. Cartron, Kinetics of DNA methylation inheritance by the Dnmt1-including complexes during the cell cycle, Cell Div, vol.7, p.5, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00680687

C. Brenner, R. Deplus, and C. Didelot, Myc represses transcription through recruitment of DNA methyltransferase corepressor, EMBO J, vol.24, issue.2, pp.336-346, 2005.

E. Hervouet, F. M. Vallette, and P. F. Cartron, Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation, Epigenetics, vol.4, issue.7, pp.487-499, 2009.

C. Blanquart, C. Linot, P. F. Cartron, D. Tomaselli, A. Mai et al., Epigenetic metalloenzymes, Curr. Med. Chem, vol.26, issue.15, pp.2748-2785, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01885512

S. Reuter, S. C. Gupta, B. Park, A. Goel, and B. B. Aggarwal, Epigenetic changes induced by curcumin and other natural compounds, Genes Nutr, vol.6, issue.2, pp.93-108, 2011.

M. Billam, M. D. Sobolewski, and N. E. Davidson, Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells, Breast Cancer Res. Treat, vol.120, issue.3, pp.581-592, 2010.

K. Kim, S. J. Park, and J. Kim, First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies, Invest. New Drugs, vol.33, issue.5, pp.1048-1057, 2015.

S. Muller, P. Filippakopoulos, and S. Knapp, Bromodomains as therapeutic targets, Expert Rev. Mol. Med, vol.13, p.29, 2011.

R. J. Amato, J. Stephenson, and S. Hotte, MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma, Cancer Invest, vol.30, issue.5, pp.415-421, 2012.

B. H. Lee, S. Yegnasubramanian, X. Lin, and W. G. Nelson, Procainamide is a specific inhibitor of DNA methyltransferase 1, J. Biol. Chem, vol.280, issue.49, pp.40749-40756, 2005.

, ? Identifies a selective DNMT1 inhibitor

D. Kuck, T. Caulfield, F. Lyko, and J. L. Medina-franco, Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells, Mol. Cancer Ther, vol.9, issue.11, pp.3015-3023, 2010.

A. Rajavelu, Z. Tulyasheva, R. Jaiswal, A. Jeltsch, and N. Kuhnert, The inhibition of the mammalian DNA methyltransferase 3a (Dnmt3a) by dietary black tea and coffee polyphenols, BMC Biochem, vol.12, p.16, 2011.

X. Sun, Y. Xie, and X. Sun, The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma, Biosci. Rep, vol.39, issue.3, p.20181916, 2019.

P. Joshi, T. M. Greco, and A. J. Guise, The functional interactome landscape of the human histone deacetylase family, Mol. Syst. Biol, vol.9, p.672, 2013.

I. Livyatan and E. Meshorer, The HDAC interaction network, Mol. Syst. Biol, vol.9, p.671, 2013.

F. Pan, O. Weeks, F. C. Yang, and M. Xu, The TET2 interactors and their links to hematological malignancies, IUBMB Life, vol.67, issue.6, pp.438-445, 2015.

E. Hervouet, P. Peixoto, R. Delage-mourroux, M. Boyer-guittaut, and P. F. Cartron, Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma, Clin. Epigenetics, vol.10, p.17, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01981717

E. Hervouet, F. M. Vallette, and P. F. Cartron, Dnmt1/transcription factor interactions: an alternative mechanism of DNA methylation inheritance, Genes Cancer, vol.1, issue.5, pp.434-443, 2010.

R. Pacaud, Q. Sery, L. Oliver, F. M. Vallette, J. Tost et al., DNMT3L interacts with transcription factors to target DNMT3L/DNMT3B to specific DNA sequences: role of the DNMT3L/DNMT3B/p65-NF?B complex in the (de-)methylation of TRAF1, Biochimie, vol.104, pp.36-49, 2014.

M. M. Kronfol, M. G. Dozmorov, R. Huang, P. W. Slattum, and J. L. Mcclay, The role of epigenomics in personalized medicine, Expert Rev. Precis. Med. Drug Dev, vol.2, issue.1, pp.33-45, 2017.

A. Majchrzak-celi?ska and W. Baer-dubowska, Pharmacoepigenetics: an element of personalized therapy?, Expert Opin. Drug Metab. Toxicol, vol.13, issue.4, pp.387-398, 2017.

S. P. Kabekkodu, S. Chakrabarty, S. Ghosh, A. Brand, and K. Satyamoorthy, Epigenomics, pharmacoepigenomics, and personalized medicine in cervical cancer, Public Health Genomics, vol.20, issue.2, pp.100-115, 2017.

B. I. Díaz-eufracio, J. J. Naveja, and J. L. Medina-franco, Protein-protein interaction modulators for epigenetic therapies, Adv. Protein Chem. Struct. Biol, vol.110, pp.65-84, 2018.

?. , Supports the interest to target protein-protein interactions for the design of selective epidrugs

X. Kong, L. Chen, and L. Jiao, Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2, J. Med. Chem, vol.57, issue.22, pp.9512-9521, 2014.

G. Ferrari-amorotti, V. Fragliasso, and R. Esteki, Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion, Cancer Res, vol.73, issue.1, pp.235-245, 2013.

H. J. Kang, Y. W. Yi, and S. J. Hou, Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression of tumor suppressor genes and inhibits growth of triple-negative breast tumor, Oncotarget, vol.8, issue.48, pp.83457-83468, 2017.

. ??-a,

R. J. Harding, R. Ferreira-de-freitas, and P. Collins, Small molecule antagonists of the interaction between the histone deacetylase 6 zinc-finger domain and ubiquitin, J. Med. Chem, vol.60, issue.21, pp.9090-9096, 2017.

L. Albert, J. Xu, R. Wan, V. Srinivasan, Y. Dou et al., Controlled inhibition of methyltransferases using photoswitchable peptidomimetics: towards an epigenetic regulation of leukemia, Chem. Sci, vol.8, issue.6, pp.4612-4618, 2017.

M. Cheray, R. Pacaud, A. Nadaradjane, L. Oliver, F. M. Vallette et al., Specific inhibition of DNMT3A/ISGF3? interaction increases the temozolomide efficiency to reduce tumor growth, Theranostics, vol.6, issue.11, pp.1988-1999, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01414173

. ??-a,

M. Cheray, A. Nadaradjane, P. Bonnet, S. Routier, F. M. Vallette et al., Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness, Epigenomics, vol.6, issue.3, pp.267-275, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478615

M. Cheray, R. Pacaud, A. Nadaradjane, F. M. Vallette, and P. F. Cartron, Specific inhibition of one DNMT1-including complex influences tumor initiation and progression, Clin. Epigenetics, vol.5, issue.1, p.9, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00851207

P. Chatterjee, D. Roy, and N. Rathi, Epigenetic drug repositioning for Alzheimer's disease based on epigenetic targets in human interactome, J. Alzheimers Dis, vol.61, issue.1, pp.53-65, 2018.